Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

563 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.
Kaneda H, Okamoto I, Nakagawa K. Kaneda H, et al. Among authors: okamoto i. J Thorac Oncol. 2013 Apr;8(4):e32-3. doi: 10.1097/JTO.0b013e3182843771. J Thorac Oncol. 2013. PMID: 23486271 No abstract available.
Expression of CD44 splicing isoforms in lung cancers: dominant expression of CD44v8-10 in non-small cell lung carcinomas.
Sasaki JI, Tanabe KK, Takahashi K, Okamoto I, Fujimoto H, Matsumoto M, Suga M, Ando M, Saya H. Sasaki JI, et al. Among authors: okamoto i. Int J Oncol. 1998 Mar;12(3):525-33. doi: 10.3892/ijo.12.3.525. Int J Oncol. 1998. PMID: 9472088
Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer.
Okamoto I, Fujii K, Matsumoto M, Terasaki Y, Kihara N, Kohrogi H, Suga M. Okamoto I, et al. Lung Cancer. 2003 Jun;40(3):339-42. doi: 10.1016/s0169-5002(03)00043-6. Lung Cancer. 2003. PMID: 12781434
Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer.
Araki J, Okamoto I, Suto R, Ichikawa Y, Sasaki J. Araki J, et al. Among authors: okamoto i. Lung Cancer. 2005 Apr;48(1):141-4. doi: 10.1016/j.lungcan.2004.10.012. Epub 2004 Dec 9. Lung Cancer. 2005. PMID: 15777982
Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
Okamoto I, Moriyama E, Fujii S, Kishi H, Nomura M, Goto E, Kiyofuji C, Imamura F, Mori T, Matsumoto M. Okamoto I, et al. Jpn J Clin Oncol. 2005 Apr;35(4):188-94. doi: 10.1093/jjco/hyi059. Jpn J Clin Oncol. 2005. PMID: 15845567 Review.
EGFR mutation in gefitinib-responsive small-cell lung cancer.
Okamoto I, Araki J, Suto R, Shimada M, Nakagawa K, Fukuoka M. Okamoto I, et al. Ann Oncol. 2006 Jun;17(6):1028-9. doi: 10.1093/annonc/mdj114. Epub 2005 Dec 15. Ann Oncol. 2006. PMID: 16357019 No abstract available.
Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients.
Matsunaga Y, Hamada A, Okamoto I, Sasaki J, Moriyama E, Kishi H, Matsumoto M, Hira A, Watanabe H, Saito H. Matsunaga Y, et al. Among authors: okamoto i. Ther Drug Monit. 2006 Feb;28(1):76-82. doi: 10.1097/01.ftd.0000185771.82620.ee. Ther Drug Monit. 2006. PMID: 16418698 Clinical Trial.
Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, Ariyoshi Y, Fukuoka M. Ando M, et al. Among authors: okamoto i. J Clin Oncol. 2006 Jun 1;24(16):2549-56. doi: 10.1200/JCO.2005.04.9866. J Clin Oncol. 2006. PMID: 16735708
Down-regulation of survivin by ultraviolet C radiation is dependent on p53 and results in G(2)-M arrest in A549 cells.
Ikeda M, Okamoto I, Tamura K, Satoh T, Yonesaka K, Fukuoka M, Nakagawa K. Ikeda M, et al. Among authors: okamoto i. Cancer Lett. 2007 Apr 18;248(2):292-8. doi: 10.1016/j.canlet.2006.08.005. Epub 2006 Sep 7. Cancer Lett. 2007. PMID: 16959403
Pemetrexed-induced edema of the eyelid.
Kurata T, Tamura K, Okamoto I, Satoh T, Nakagawa K, Fukuoka M. Kurata T, et al. Among authors: okamoto i. Lung Cancer. 2006 Nov;54(2):241-2. doi: 10.1016/j.lungcan.2006.08.002. Epub 2006 Sep 22. Lung Cancer. 2006. PMID: 16996165
563 results
Jump to page
Feedback